Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2024 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Transition in epilepsy - A pilot study with patients in and outside of academic centers.
Epilepsy Behav. 2024 Feb;151:109624. doi: 10.1016/j.yebeh.2024.109624. Epub 2024 Jan 13.
Epilepsy Behav. 2024.
PMID: 38219605
Free article.
Patients were required to be 12 years or older at the time of the survey and were divided into two groups: those between 12 and 17 years and those 18 years or older. Caregivers answered on behalf of patients who were unable to respond (e.g., intellectual disa …
Patients were required to be 12 years or older at the time of the survey and were divided into two groups: those between 12 and 17 ye …
Pharmacological interventions for preventing post-traumatic stress disorder (PTSD).
Amos T, Stein DJ, Ipser JC.
Amos T, et al.
Cochrane Database Syst Rev. 2014 Jul 8;2014(7):CD006239. doi: 10.1002/14651858.CD006239.pub2.
Cochrane Database Syst Rev. 2014.
PMID: 25001071
Free PMC article.
Review.
None of the single trials of escitalopram, temazepam and gabapentin demonstrated evidence that medication was superior to placebo in preventing the onset of PTSD.Seven of the included RCTs were at a high risk of bias. Differential drop-outs between groups undermined the re …
None of the single trials of escitalopram, temazepam and gabapentin demonstrated evidence that medication was superior to placebo in prevent …
Item in Clipboard
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study.
De Giorgis V, Bhatia KP, Boespflug-Tanguy O, Gras D, Marina AD, Desurkar A, Toledo M, Miller I, Rotstein M, Schneider SA, Tarquinio DC, Weber Y, Brandabur M, Mayhew J, Koutsoukos T, De Vivo DC.
De Giorgis V, et al.
Mov Disord. 2024 May 9. doi: 10.1002/mds.29822. Online ahead of print.
Mov Disord. 2024.
PMID: 38725190
The study was closed early during the open-label extension because of lack of effectiveness. ...Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society....
The study was closed early during the open-label extension because of lack of effectiveness. ...Movement Disorders published by Wiley …
Item in Clipboard
Cite
Cite